Medication Competition Act

Hozzl · 2026-05-12T21:15:08Z

Explore the details of Senate Bill 4332 Medication Competition Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

5/12/2026, 9:15 PM

Summary of Bill S 4332

This bill, introduced in the 119th Congress as S.4332 on April 16, 2026, aims to mandate the Secretary of Health and Human Services to assess the exclusivity periods applicable to licensed biological products, specifying the eligibility criteria for such periods.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4332

Bill S 4332 is currently in the status of Bill Introduced since April 16, 2026. Bill S 4332 was introduced during Congress 119 and was introduced to the Senate on April 16, 2026. Bill S 4332's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of April 16, 2026

Bipartisan Support of Bill S 4332

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4332

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4332

A bill to require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible.